Welcome to Cabometyx.no website. This website is intended for Norway Healthcare professionals only.
Please confirm below that you are a registered healthcare professional.
I AM A NORWEGIAN HEALTHCARE PROFESSIONAL
(a)HCC | (advanced) Hepatocellular Carcinoma |
(a)RCC | (advanced) Renal Cell Carcinoma |
(HR)QoL | (Health Related) Quality of Life |
(m)RECIST | (modified) Response Evaluation Criteria In Solid Tumors |
AE | Adverse Event |
AFP | Alpha FetoProtein |
AASLD | American Association for the Study of Liver Disease |
ASCO | American Society of Clinical Oncology |
A-Pac | Asia Pacific |
A&U | Awareness and Usage |
BCLC | Barcelona Clinic Liver Cancer |
BSC | Best Supportive Care |
BMS | Bristol Myers Squibb |
BU | Business Unit |
CRPC | Castration Resistant Prostate Cancer |
CPI | Check Point Inhibitor |
CM | CheckMate |
CP-A | Child Pugh-A |
CSR | Clinical Study Report |
CHMP | Committee for Medicinal Products for Human Use |
CT-Scan | Computed Tomography Scan |
CME | Continuing Medical Education |
CSF | Critical Success Factor |
DCR | Disease Control Rate |
DoT | Duration of Treatment |
ECOG | Eastern Cooperative Oncology Group |
ER | Emergency |
EASL | European Association for the Study of the Liver |
EAU | European Association of Urology |
EC | European Commission |
EFPIA | European Federation of Pharmaceutical Industries and Associations |
EIKCS | European International Kidney Cancer Symposium |
ELPA | European Liver Patient Association |
EMA | European Medicine Agency |
ESMO | European Society of Molecular Oncology |
EU | European Union |
G-BA | German Federal Joint Committee |
1L / 2L | First line / Second Line |
FPI | First Patient In |
FDA | Food and Drug Administration |
FYROM | Former Yugoslavian Republic of Macedonia |
EU5 | France, Germany, Italy, Spain, UK |
EU3 | France, Germany, UK |
GI | Gastro Intestinal |
GE | GastroEnteric |
GU | GenitoUrinary |
DACH | Germany, Austria, Switzerland |
GCSP | Globcal Cabometyx Strategic Plan |
GAS-6 | Growth arrest-specific 6 (AXL ligand) |
HAS | Haute Autorité de Santé (French National Authority for Health) |
HR | Hazard Ratio |
HCP | Health Care Provider |
HEOR | Health Economics Outcome Research |
HTA | Health Technology Assessment |
HBV | Hepatitis B Virus |
HCV | Hepatitis C Virus |
HGF | Hepatocyte Growth Factor (MET ligand) |
MET | Hepatocyte growth factor receptor |
HEP | Hepatologists |
IME | Independent Medical Education |
IRC | Independent Review Committee |
IDO-1 | Indoleamine-pyrrole 2,3-dioxygenase |
IKCC | International Kidney Cancer Coalition |
ILCA | International Liver Cancer Association |
IIME | Ipsen Initiated Medical Education |
ISS | Ipsen Sponsored Study |
KAM | Key Account Manager |
KPI | Key Performance Indicator |
LPI | Last Patient In |
LPLV | Last Patient Last Visit |
LCM | Life Cycle Management |
LDT | Liver Directed Therapies |
mToR | mammalian Target of Rapamycin |
MEA | Managed Entry Agreement |
MoA | Mechanism of Action |
MTC | Medullary Thyroid Cancer |
MSD | Merck Sharp and Dohme |
MC(M) | MultiChannel (Marketing) |
NICE | National Institute for Health and Care Excellence |
NMA | Network Meta Analysis |
NIS | Non Interventional Study |
NSCLC | Non Small Cell Lung Cancer |
Nordics | Norway, Sweden, Finland, Denmark |
NA | Not Available |
NR | Not Reached |
ISPOR | International Society for Pharmacoeconomics and Outcomes Research |
ORR | Objective Response Rate |
ONC | Oncologists |
OS | Overall Survival |
PVP | Payer Value Proposition |
PS | Performance status |
PK | PhamacoKinetic |
Portable Document File | |
P&R | Price & Reimbursement |
P&MA | Pricing & Market Access |
PCP | Primary Care Provider |
PE | Primary Endpoint |
PI | Principal Education |
PFS | Progression Free Survival |
Q&A | Question and Answers |
RET | Rearranged during transfection (proto oncogene) |
R&D | Research & Development |
RoW | Rest of the World |
ROI | Return on Investment |
SoC | Standard of Care |
T/C | Teleconference |
TL | Thought Leader |
TBC | To Be Confirmed |
TBD | To Be Determined |
Tx | Treatment |
Rx | Prescription Treatment |
TRAE | Treatment Related Adverse Events |
TKI | Tyrosine Kinase Inhibitor |
USA | United States of America |
UC | Urothelial Cancer |
VEGF(R) | Vascular Endothelial Growth Factor (Receptor) |
WG | Working group |
WCGI | World Congress on GI Cancer |
WKCD | World Kidney Cancer Day |
I AM A NORWEGIAN HEALTHCARE PROFESSIONAL